Magro again
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Magro again
would imagine that make Geron more attractive for acquisition
Re: Magro again
https://x.com/Dr_AmerZeidan/status/1755 ... 80056?s=20
I would expect him to be part of the ADCOM - he was disappointed imetelstat was not approved in 2023
I would expect him to be part of the ADCOM - he was disappointed imetelstat was not approved in 2023
Re: Magro again
Thanks for posting link.
Here is what Dr. Zeidan wrote on Twitter:
A very sad end to the story of Magrolimab in #MDSsm and #AMLsm. There is a lot to be learned here not only in terms of the science of the CD47 pathway, but also in terms of trial design, endpoints, & overall drug development approach. https://targetedonc.com/view/fda-halts- ... in-aml-mds via
@targetedonc
Here is what Dr. Zeidan wrote on Twitter:
A very sad end to the story of Magrolimab in #MDSsm and #AMLsm. There is a lot to be learned here not only in terms of the science of the CD47 pathway, but also in terms of trial design, endpoints, & overall drug development approach. https://targetedonc.com/view/fda-halts- ... in-aml-mds via
@targetedonc
-
biopearl123
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Magro again
Guys, thanks for posting. It will be very interesting to see who the FDA asks to be on the ADCOM.